{
    "clinical_study": {
        "@rank": "151422", 
        "arm_group": [
            {
                "arm_group_label": "EVP-6308; Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "low dose, Capsule, Twice Daily, Day 1 through Day 3"
            }, 
            {
                "arm_group_label": "EVP-6308; Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3"
            }, 
            {
                "arm_group_label": "EVP-6308; Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "high intermediate dose, Capsule, Once Daily, Day 1 through Day 3"
            }, 
            {
                "arm_group_label": "EVP-6308; Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "high dose, Capsule, Once Daily, Day 1 through Day 3"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose-\n      and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting\n      phosphodiesterase 10 (PDE10)] by EVP-6308."
        }, 
        "brief_title": "Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Healthy male or female volunteers, 18 to 50 years of age\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities on physical examination, medical history,  ECG ,\n             vital signs, laboratory values, or unstable medical or psychiatric illness\n\n          -  Any disorder that may interfere with drug absorption.\n\n          -  Clinically significant allergy or sensitivity to medications Positive test for human\n             immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C\n             antibody.\n\n          -  Pregnant or breast feeding.\n\n          -  History of exposure to any radiation >15 mSv/year (e.g., occupational or radiation\n             therapy) over the past year."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001389", 
            "org_study_id": "EVP-6308-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "EVP-6308; Arm 1", 
                "EVP-6308; Arm 2", 
                "EVP-6308; Arm 3", 
                "EVP-6308; Arm 4"
            ], 
            "description": "Arms 1, 2, 3, 4", 
            "intervention_name": "EVP-6308", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Enzyme occupancy", 
            "Positron emission tomography (PET)", 
            "Phosphodiesterase 10 inhibitor"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label, Multiple Ascending Dose, [18F]MNI-659 PET-Imaging Study to Evaluate PDE10A Occupancy After Dosing With EVP-6308 in Healthy Subjects", 
        "overall_contact": {
            "email": "nbuerstatte@forumpharma.com", 
            "last_name": "Nathan Buerstatte", 
            "phone": "617-374-5784"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in binding potential.", 
            "measure": "Target occupancy of [18F]MNI-659.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Day 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following will be evaluated: clinical laboratory evaluations (chemistry, hematology, coagulation and urinalysis), physical examination, directed neurological examination, vital signs, orthostatic blood pressure, 12-lead ECG, and assessment for suicidality.  Adverse events and concomitant medications will be collected from the time of signing the informed consent.", 
                "measure": "Safety of EVP-6308 as assessed by adverse events, vital signs, clinical laboratory tests, C-SSRS, and electrocardiogram (ECG).", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 4 or Early Termination"
            }, 
            {
                "description": "Pharmacokinetic parameters to be determined include Cmax, Tmax, t1/2, and CL/F.", 
                "measure": "Pharmacokinetics of EVP-6308 and EVP-6308 N-oxide.", 
                "safety_issue": "No", 
                "time_frame": "Day 3"
            }
        ], 
        "source": "FORUM Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FORUM Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}